It does not come as a surprise that mutations in the glycine-rich loop can interfere with ligand binding and thus mediate resistance to kinase inhibitors as it was described previously for chronic myelogenous leukemia, where mutations in the glycine-rich loop in BCR-ABL cause resistance to imatinib28,29. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.